ACCESSWIRE

The newsfeed available here is provided by our content partner ACCESSWIRE. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.

The NewsWire Hub ("X-Billboard") currently comprises five of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
System-State: Number of processed items 3.491 Notifications successully processed since Inception

ACCESSWIRE is an important news source for private investors, investors and traders that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market players in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can use the detailed views of the info cards to directly access the respective news item and other analysis tools.

NEWS
EXPLORER
US74366E1029
State: 22.11.2024 | 3AM
Do you already know our new terminal view? Click here.
FIGI: BBG002B63KM7
PTGX

Protagonist Therapeutics, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Protagonist Therapeutics, Inc.
ISIN
US74366E1029
TICKER
PTGX
MIC
XNAS
REUTERS
PTGX.OQ
BLOOMBERG
PTGX US
Thu, 21.11.2024       Protagonist Therapeutics

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, ...
Protagonist Therapeutics
Tue, 19.11.2024       Protagonist Therapeutics

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 ant...
Protagonist Therapeutics
Mon, 18.11.2024       Protagonist Therapeutics

NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor in plaque psoriasisICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16...
Protagonist Therapeutics
Thu, 07.11.2024       Protagonist Therapeutics

Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025Top line results for rusfertide Phase 3 VERIFY clinical trial in polycyth...
Protagonist Therapeutics
Tue, 05.11.2024       Protagonist Therapeutics

NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in ...
Protagonist Therapeutics
Tue, 29.10.2024       Protagonist Therapeutics

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 sh...
Protagonist Therapeutics

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.


On behalf of the international investor community, we would like to thank AccessWire for providing the news and data feeds